DD244292A5 - Trockensubstanzen und stabile suspensionen - Google Patents

Trockensubstanzen und stabile suspensionen Download PDF

Info

Publication number
DD244292A5
DD244292A5 DD85282435A DD28243585A DD244292A5 DD 244292 A5 DD244292 A5 DD 244292A5 DD 85282435 A DD85282435 A DD 85282435A DD 28243585 A DD28243585 A DD 28243585A DD 244292 A5 DD244292 A5 DD 244292A5
Authority
DD
German Democratic Republic
Prior art keywords
polyethylene glycol
preparation
androstene
hydroxy
dry substances
Prior art date
Application number
DD85282435A
Other languages
German (de)
English (en)
Inventor
Leo Geller
Peter Glanzmann
Original Assignee
����`��@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ����`��@���k�� filed Critical ����`��@���k��
Publication of DD244292A5 publication Critical patent/DD244292A5/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Drying Of Solid Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Magnetic Record Carriers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DD85282435A 1984-11-06 1985-11-04 Trockensubstanzen und stabile suspensionen DD244292A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH530584 1984-11-06

Publications (1)

Publication Number Publication Date
DD244292A5 true DD244292A5 (de) 1987-04-01

Family

ID=4291364

Family Applications (1)

Application Number Title Priority Date Filing Date
DD85282435A DD244292A5 (de) 1984-11-06 1985-11-04 Trockensubstanzen und stabile suspensionen

Country Status (26)

Country Link
US (1) US5002940A (xx)
EP (2) EP0181287B1 (xx)
JP (2) JPS61204118A (xx)
KR (1) KR890000907B1 (xx)
AT (2) ATE51152T1 (xx)
AU (2) AU586988B2 (xx)
CA (1) CA1249223A (xx)
CY (2) CY1898A (xx)
DD (1) DD244292A5 (xx)
DE (2) DE3587020D1 (xx)
DK (1) DK162510C (xx)
ES (1) ES8701491A1 (xx)
FI (1) FI85809C (xx)
GR (1) GR852637B (xx)
HK (2) HK101192A (xx)
HU (1) HU195728B (xx)
IE (2) IE63166B1 (xx)
IL (1) IL76943A (xx)
MX (1) MX9203371A (xx)
NL (1) NL940015I2 (xx)
NO (1) NO169324C (xx)
NZ (2) NZ214069A (xx)
PH (1) PH21673A (xx)
PT (1) PT81429B (xx)
SG (1) SG107192G (xx)
ZA (1) ZA858481B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH673395A5 (xx) * 1987-01-30 1990-03-15 Ciba Geigy Ag
MX9201782A (es) * 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
AU1787800A (en) * 1998-12-08 2000-06-26 Phares Pharmaceutical Research N.V. Phospholipid compositions
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6487907B1 (en) * 1999-07-08 2002-12-03 California Institute Of Technology Microgyroscope with integrated vibratory element
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US10987303B2 (en) 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2068447A1 (en) * 1969-11-26 1971-08-27 Orsymonde Dehydrated pharmaceutical comps by - lyophilisation
LU77457A1 (xx) * 1977-05-31 1979-01-19
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58206513A (ja) * 1982-05-28 1983-12-01 Eisai Co Ltd セクレチン吸着防止組成物および方法
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
DK79184A (da) * 1983-02-23 1984-08-24 Sanofi Sa Fungicide farmaceutiske midler indeholdende et imidazolderivat
EP0226021A1 (de) * 1985-12-12 1987-06-24 BBC Brown Boveri AG Thyristor mit schaltbarem Emitter-Kurzschluss

Also Published As

Publication number Publication date
KR860003825A (ko) 1986-06-13
ATE84718T1 (de) 1993-02-15
EP0181287B1 (de) 1990-03-21
DE3576650D1 (de) 1990-04-26
DE3587020D1 (de) 1993-03-04
EP0346953A2 (de) 1989-12-20
HUT42936A (en) 1987-09-28
KR890000907B1 (ko) 1989-04-13
AU586988B2 (en) 1989-08-03
JPH0558410B2 (xx) 1993-08-26
IE902490L (en) 1986-05-06
US5002940A (en) 1991-03-26
ATE51152T1 (de) 1990-04-15
EP0346953A3 (en) 1990-11-22
IE63156B1 (en) 1995-03-22
NL940015I2 (nl) 1997-01-06
FI854330A (fi) 1986-05-07
FI85809C (fi) 1992-06-10
EP0346953B1 (de) 1993-01-20
DK162510B (da) 1991-11-11
AU633844B2 (en) 1993-02-11
PT81429B (pt) 1988-03-03
GR852637B (xx) 1986-03-04
IE63166B1 (en) 1995-03-22
PH21673A (en) 1988-01-13
FI854330A0 (fi) 1985-11-04
DK509485A (da) 1986-05-07
ES548492A0 (es) 1986-12-01
EP0181287A2 (de) 1986-05-14
HK192095A (en) 1995-12-29
NO854403L (no) 1986-05-07
HK101192A (en) 1992-12-24
ES8701491A1 (es) 1986-12-01
PT81429A (en) 1985-12-01
EP0181287A3 (en) 1987-09-23
MX9203371A (es) 1992-09-01
NZ214069A (en) 1989-08-29
AU4934485A (en) 1986-05-15
JPH0768130B2 (ja) 1995-07-26
IL76943A (en) 1990-02-09
NZ229276A (en) 1989-08-29
CA1249223A (en) 1989-01-24
IE852755L (en) 1986-05-06
AU4150489A (en) 1990-01-04
NO169324C (no) 1992-06-10
JPH0648945A (ja) 1994-02-22
DK162510C (da) 1992-03-30
FI85809B (fi) 1992-02-28
CY1898A (en) 1985-10-31
JPS61204118A (ja) 1986-09-10
SG107192G (en) 1992-12-24
NO169324B (no) 1992-03-02
CY1677A (en) 1993-10-10
ZA858481B (en) 1986-06-25
DK509485D0 (da) 1985-11-05
NL940015I1 (nl) 1994-10-17
HU195728B (en) 1988-07-28

Similar Documents

Publication Publication Date Title
DE69734742T2 (de) Arzneizusammensetzungen enthaltend Ascomycinderivate
DE2601207C3 (de) Verfahren zur Herstellung einer flüssigen pharmazeutischen Zubereitung mit gesteuertem Arzneimittelabgabevermögen
DE69839224T2 (de) Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide
DE60116084T2 (de) Parenteral anzuwendende stabilisierte wässrige suspensionen
DE69936911T2 (de) Propofolhaltiges arzneimittel enthaltend sulfite
DE602004000982T2 (de) Intranasale formulierung mit rotigotin
DE60105322T2 (de) Wässerige zusammensetzung enthaltend amphotericin b
DE69920201T2 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
EP0733372A2 (de) Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
CH693764A5 (de) Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat.
DE3008082A1 (de) Carcinostatisches und die immunreaktion stimulierendes mittel, enthaltend lysophospholipid und phospholipid, und verfahren zur herstellung desselben
EP0711556A1 (de) Intravenöse Lösungen für ein Staurosporinderivat
DE1792410B2 (de) Arzneimittelzubereitung zur intravenösen Injektion
WO2005115386A1 (de) Flüssige zubereitung für die veterinärmedizin; verfahren zu deren herstellung und deren verwendung
EP0181287B1 (de) Trockensubstanzen und stabile Suspensionen
DE60106647T2 (de) Klare propofolzusammensetzungen
EP0675709B1 (de) Lyopilisierte, wirkstoffhaltige emulsion
EP0705601A1 (de) Lösungen von Anthrachinonen zur parenteralen Applikation
EP0336000B1 (de) Ambiphile Creme
DE4038385A1 (de) Sitosterol und seine glykoside mit verbesserter bioverfuegbarkeit
WO1997021428A1 (de) Cortisolspray zur topischen verabreichung
DE1620629C3 (de) Verwendung eines Salzes von 2-Merkaptoäthansulf onsäure zur Herstellung von Mukolytica
DE60120630T2 (de) Pharmazeutische Zusammensetzung enthaltend Xanthangummi
DE69922252T2 (de) Parenterale lösungen enthaltend propofol (2,6-diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol als lösungsmittel
DE60127140T2 (de) Amphotericin b enthaltende strukturierte emulsion

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee